Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.

Abstract

OBJECTIVE: To describe the prevalence, incidence and predictors of severe anaemia in previously untreated symptomatic HIV-infected adults with CD4+ T-cells 3 initiating zidovudine-containing regimens in Africa. DESIGN: DART is a randomized trial comparing two strategies for HIV/AIDS management in Uganda and Zimbabwe. Methods: We analysed the occurrence of anaemia at weeks 4 and 12, and then every 12 weeks. We also evaluated sex, age, WHO stage, body mass index (BMI), baseline laboratory measurements and first regimen as predictors of developing grade 4 anaemia (3 and median baseline haemoglobin=11.4 g/dl) had a median 72 weeks follow-up. Prevalence of grade 4 anaemia was 0.7%, 2.0%, 0.5% and

Citation

Ssali, F.; Stöhr, W.; Munderi, P.; Reid, A.; Walker, A.S.; Gibb, D.M.; Mugyenyi, P.; Kityo, C.; Grosskurth, H.; Hakim, J.; Darbyshire, J.H.; Gilks, C.F; DART Trial Team. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antiviral Therapy (2006) 11 (6) 741-749.

Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.